BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37017467)

  • 1. Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis.
    Qie W; Zhao Q; Yang L; Zou B; Duan Y; Yao Y; Wang L
    Cancer Med; 2023 Jul; 12(13):13873-13884. PubMed ID: 37017467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.
    Suh CH; Kim KW; Pyo J; Hatabu H; Nishino M
    Lung Cancer; 2019 Jun; 132():79-86. PubMed ID: 31097098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
    Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
    Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Suh CH; Park HS; Kim KW; Pyo J; Hatabu H; Nishino M
    Lung Cancer; 2018 Sep; 123():60-69. PubMed ID: 30089596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors.
    Zhou F; Yang Y; Zhang L; Cheng Y; Han B; Lu Y; Wang C; Wang Z; Yang N; Fan Y; Wang L; Ma Z; Zhang L; Yao Y; Zhao J; Dong X; Zhu B; Zhou C
    ESMO Open; 2023 Jun; 8(3):101560. PubMed ID: 37230029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
    Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
    Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
    Sugawara S; Kondo M; Yokoyama T; Kumagai T; Nishio M; Goto K; Nakagawa K; Seto T; Yamamoto N; Kudou K; Asato T; Zhang P; Ohe Y
    Int J Clin Oncol; 2022 Dec; 27(12):1828-1838. PubMed ID: 36036294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.
    Tao Y; Zhou Y; Tang L; Chen H; Feng Y; Shi Y
    Invest New Drugs; 2022 Aug; 40(4):831-840. PubMed ID: 35435628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study.
    Ma Z; Pei J; Zhang Y; Li H; Sun D; Zhang Y; An Z
    Expert Opin Drug Saf; 2023 Mar; 22(3):237-242. PubMed ID: 35924402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials.
    Zhao J; Ma Z; Li H; Sun D; Hu Y; Zhang C; Zhang Y
    Expert Opin Drug Saf; 2023; 22(7):581-588. PubMed ID: 36803384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
    Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
    Zhao M; Liu S; Xie R; Zhang J; Li J
    Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: Clinical and radiologic characteristics and risk factors.
    Hwang HJ; Kim MY; Choi CM; Lee JC
    Medicine (Baltimore); 2019 Nov; 98(48):e18131. PubMed ID: 31770246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
    Wang M; Slatter S; Sussell J; Lin CW; Ogale S; Datta D; Butte AJ; Bazhenova L; Rudrapatna VA
    Target Oncol; 2023 Jul; 18(4):571-583. PubMed ID: 37341856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
    Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K
    Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
    Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.